The browser doesnot support javascript
Print Plan Forms |

Medication Safety Alerts

Amneal Epinephrine Injection Product Safety Alert

6/01/2020

On June 1, 2020, the United States Food and Drug Administration (FDA) issued a notice alerting patients, caregivers and health care professionals to immediately inspect certain lots of Amneal and Impax epinephrine auto-injector 0.3 mg to ensure the yellow “stop collar” in the device is present.

In letters to health care professionals and consumers, Impax Laboratories LLC, a subsidiary of Amneal Pharmaceuticals LLC, the manufacturer of the epinephrine auto-injector, detailed how certain lots of these devices might not contain the yellow “stop collar” component. If the auto-injector is missing the yellow “stop collar” component, the device has the potential safety risk of delivering a double dose of epinephrine to a patient. It is vital for lifesaving products to work as designed in an emergency situation.

Patients, pharmacists and health care professionals who have received Amneal or Impax’s epinephrine auto-injector after December 20, 2018, should immediately visually inspect the auto-injector to confirm the presence of the yellow “stop collar” by:

  • Removing the auto-injector from the carrying case.
  • Placing the auto-injector on a flat surface.
  • Locating the edge of the label that states, “Peel here for further instructions.” Lift the label edge until you see the clear part of the auto-injector.
  • Looking for the yellow “stop collar” inside the clear part of the auto-injector. If the yellow “stop collar” is not visible inside the clear part of the auto-injector, gently rotate the blue sheath remover, without pulling or removing the blue sheath remover, to observe if the yellow “stop collar” comes into view inside the clear part of the auto-injector.
  • If yellow “stop collar” is present, then the product is safe to use, and no further action is necessary. Re-wrap the label to its original position and place the auto-injector into the carrying case.

Patients and health care professionals should contact the Amneal Drug Safety Department toll-free at 1-877-835-5472 to assist in determining if the yellow “stop collar” is missing and to make arrangements to return defective devices and obtain a replacement at no additional cost. Patients should contact their pharmacy regarding a replacement epinephrine auto-injector before returning the defective device to Amneal.

The FDA recommends that patients inspect their auto-injector devices as soon as possible and immediately contact the Amneal Drug Safety Department if they have questions about inspecting their auto-injector device, or if they’re unsure if the yellow “stop collar” is missing.

The yellow “stop collar” is one of several components that work together to assure proper dosing of the auto-injector. While some patients require a second dose of epinephrine, an epinephrine overdose has the potential to cause severe patient harm or death. As stated on the product label, consumers should always seek emergency medical help right away after using their epinephrine auto-injector.

The FDA reminds patients and health care professionals that epinephrine auto-injectors are available through additional manufacturers.

CVS Caremark? Response: CVS Caremark? Mail Service Pharmacy will continue to dispense these products. For more information, please call a Customer Care representative at the toll-free number listed on your benefit ID card.

If you are currently taking epinephrine auto-injector 0.3 mg and have questions, please call your doctor or call the Amneal Drug Safety Department toll-free at 1-877-835-5472. You may also call the FDA consumer inquiry line toll-free at 1‑888‑INFO‑FDA (1‑888‑463‑6332) or visit https://www.fda.gov.

The CVS/caremark™ app lets you manage your prescription benefits on the go. Download it now:

CVS Health LogoCVS Pharmacy LogoCVS Minute Clinic LogoCVS Specialty LogoSilverscript LogoAccordant Logo

Copyright ? 2020 CVS Caremark. All rights reserved| Terms and Conditions | Privacy Policy | Accessibility | Member Rights & Responsibilities